0000874015-18-000007.txt : 20180102 0000874015-18-000007.hdr.sgml : 20180102 20180102204955 ACCESSION NUMBER: 0000874015-18-000007 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20180101 FILED AS OF DATE: 20180102 DATE AS OF CHANGE: 20180102 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: Monia Brett P CENTRAL INDEX KEY: 0001537529 FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 000-19125 FILM NUMBER: 18503175 MAIL ADDRESS: STREET 1: 2855 GAZELLE COURT STREET 2: C/O ISIS PHARMACEUTICALS, INC. CITY: CARLSBAD STATE: CA ZIP: 92010 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: IONIS PHARMACEUTICALS INC CENTRAL INDEX KEY: 0000874015 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 330336973 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: 2855 GAZELLE COURT CITY: CARLSBAD STATE: CA ZIP: 92010 BUSINESS PHONE: 7609319200 MAIL ADDRESS: STREET 1: 2855 GAZELLE COURT CITY: CARLSBAD STATE: CA ZIP: 92010 FORMER COMPANY: FORMER CONFORMED NAME: ISIS PHARMACEUTICALS INC DATE OF NAME CHANGE: 19930328 4 1 edgar.xml PRIMARY DOCUMENT X0306 4 2018-01-01 0000874015 IONIS PHARMACEUTICALS INC IONS 0001537529 Monia Brett P C/O IONIS PHARMACEUTICALS, INC. 2855 GAZELLE COURT CARLSBAD CA 92010 0 1 0 0 SVP, Antisense Drug Discovery Common Stock 2018-01-01 2018-01-01 5 J 0 156 42.755 A 11782 D Common Stock 2018-01-02 2018-01-02 4 S 0 163 50.00 D 11619 D Employee Stock Option (right to buy) 49.25 2018-01-02 2018-01-02 4 A 0 58125 0 A 2019-01-02 2025-01-01 Common Stock 58125 58125 D Reporting 156 shares acquired under the Ionis Pharmaceuticals, Inc. Amended and Restated 2000 Employee Stock Purchase Plan on January 1, 2018. These 156 shares may not be sold until July 2, 2018. Grant of 1/2/2018 to reporting person of stock options under the Ionis Pharmaceuticals, Inc. 2011 Equity Incentive Plan. 25% of the shares subject to the option vest and become exercisable on 1/2/2019. Thereafter, the remaining shares subject to the option vest and become exercisable in 36 equal monthly installments, at the rate of 14,531 shares per year. Following this transaction, the option was exercisable as to 0 on 1/2/2018. The sale reported in this Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on 7/31/2014. /s/B. Lynne Parshall, attorney-in-fact 2018-01-02